ISSN: 1300-7777 E-ISSN: 1308-5263
Activated Protein C Resistance in Polycythemia Vera [Turk J Hematol]
Turk J Hematol. 2001; 18(3): 157-164

Activated Protein C Resistance in Polycythemia Vera

Alp Günay1, Ahmet Öztürk1, Tülin Budak2, Uğur Özbek3, Necdet Üskent1
1Department Of Haematology-oncology, Gata Haydarpaşa Training Hospital, İstanbul, Turkey
2Department Of Haematology, Marmara University Hospital, İstanbul, Turkey
3Institute For Experimental Medicine Department Of Genetics, İstanbul, Turkey

Activated protein C resistance is a result of a point mutation in factor V gene (Leiden mutation) and can be identified in approximately 50% of patients with thrombosis, making it an important risk factor for thrombosis. The aim of this study is to evaluate the role activated protein C resistance in the hypercoagulable state seen in polycythemia vera. We compared patients with polycythemia vera (n: 24) for increased risk of thromboembolism and activated protein C resistance, with the results of patients with chronic myelogenous leukemia (n: 27) and healthy control group (n: 52). Activated protein C resistance test and factor VIII activity was determined by an aPTT based test. Anticardiolipin antibodies IgG and IgM were also determined by ELISA. Leiden mutation was studied with polymerase chain reaction. Venous thromboses were observed in 12.5% and arterial thromboses in 41.6% of patients with polycythemia vera. Arterial thromboses were recognized in 7.4% of patients with chronic myelogenous leukemia. Activated protein C resistance was identified in 20.8% of patients with polycythemia vera and 14.8% with chronic myelogenous leukemia (versus 1.8% of healthy control subjects). The risk of thrombosis in patients with polycythemia vera was independent from the presence of activated protein C resistance. Leiden mutation was observed in only 1 patient out of 4 patients with chronic myelogenous leukemia who had activated protein C resistance, but not thrombosis. Factor VIII levels of patients with chronic myelogenous leukemia (158% ± 14) were higher than healthy control subjects (99% ± 15) (p< 0.05). Patients with activated protein C resistance in both groups had no seropositivity for anticardiolipin antibodies IgG and IgM. Activated protein C resistance and in some cases its association with Leiden mutation in polycythemia vera may not have a major role in the pathogenesis of thromboembolic complications of polycythemia vera.

Keywords: Activated protein C resistance, Polycythemia vera, Chronic myelogenous leukemia.


Alp Günay, Ahmet Öztürk, Tülin Budak, Uğur Özbek, Necdet Üskent. Activated Protein C Resistance in Polycythemia Vera. Turk J Hematol. 2001; 18(3): 157-164

Corresponding Author: Ahmet Öztürk, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686